Table of Contents Table of Contents
Previous Page  955 / 1119 Next Page
Information
Show Menu
Previous Page 955 / 1119 Next Page
Page Background

G≥1: 89%

G≥2: 29%

G≥3: 4%

Vaginal morbidity after definitive

radiochemotherapy + IGABT in LACC

• N=588 LACC within EMBRACE

study

• Prospective assessment of

morbidity (CTCAE 3)

at baseline and regular follow-ups

(median 15 months)

• Endpoints: vaginal stenosis,

dryness, mucositis, bleeding,

fistula

Kirchheiner et al.

IJROBP 2014